INAB Stock Summary and Trading Ideas (In8bio | NASDAQ:INAB)

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.

In8bio trades on the NASDAQ stock market under the symbol INAB.

As of February 20, 2026, INAB stock price declined to $1.53 with 18,555 million shares trading.

INAB has a beta of 1.85, meaning it tends to be more sensitive to market movements. INAB has a correlation of 0.07 to the broad based SPY ETF.

INAB has a market cap of $14.93 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, INAB traded as high as $118.50 and as low as $1.17.

The top ETF exchange traded funds that INAB belongs to (by Net Assets): VXF, VTI.

INAB has underperformed the market in the last year with a price return of -82.7% while the SPY ETF gained +13.6%. INAB has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -5.6% and -19.5%, respectively, while the SPY returned +4.2% and +1.6%, respectively.

INAB support price is $1.51 and resistance is $1.69 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INAB shares will trade within this expected range on the day.